EQT agreed to acquire Qiagen in an all-cash deal valuing the diagnostics and life-science tools provider at about €10.8 billion (roughly $12.1 billion), taking it private. The transaction follows years of interest and intermittent takeover discussions. Qiagen said its boards concluded that the move offers the best path for its next growth phase, citing greater flexibility for long-term investment under private ownership. EQT structured the bidder entity through Crown NL Bidco and includes co-investors linked to Abu Dhabi Investment Authority and CPP Investments. Shareholders would receive cash based on the terms of the tender offer, with the bid representing a premium to recent trading levels. Qiagen will remain independent under current management until deal completion. The deal highlights continued investor appetite for high-cash-flow life-sciences tools businesses and could affect how Qiagen prioritizes R&D and diagnostics expansion.